Big Pharma Split (FRA:XN4) Cash-to-Debt : No Debt ⁽¹⁾ (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Big Pharma Split Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Big Pharma Split's cash to debt ratio for the quarter that ended in Jun. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Big Pharma Split could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Big Pharma Split's Cash-to-Debt or its related term are showing as below:

FRA:XN4' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 7 years, Big Pharma Split's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

FRA:XN4's Cash-to-Debt is ranked better than
99.66% of 1455 companies
in the Asset Management industry
Industry Median: 5.53 vs FRA:XN4: No Debt

Big Pharma Split Cash-to-Debt Historical Data

The historical data trend for Big Pharma Split's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Big Pharma Split Cash-to-Debt Chart

Big Pharma Split Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Big Pharma Split Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash-to-Debt	Get a 7-Day Free Trial									No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Big Pharma Split's Cash-to-Debt

For the Asset Management subindustry, Big Pharma Split's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Big Pharma Split's Cash-to-Debt Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, Big Pharma Split's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Big Pharma Split's Cash-to-Debt falls into.

Big Pharma Split Cash-to-Debt Calculation

This is the ratio of a company's Balance Sheet Cash And Cash Equivalents to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Big Pharma Split's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Big Pharma Split had no debt ⁽¹⁾.

Big Pharma Split's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Big Pharma Split had no debt ⁽¹⁾.

Big Pharma Split (FRA:XN4) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Big Pharma Split Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Big Pharma Split's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Big Pharma Split Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Big Pharma Split Corp (FRA:XN4) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

PRM.PR.A.PFD:Canada PRM:Canada

Address

610 Chartwell Road, Suite 204, Oakville, ON, CAN, L6J 4A5

Website

https://www.harvestportfolios.com

Big Pharma Split Corp is a mutual fund corporation. Its investment objective is to provide shareholders with fixed cumulative preferential quarterly cash distributions, and regular monthly cash distributions. The company has a presence in the United States; Switzerland; France and United Kingdom.

Big Pharma Split Headlines

No Headlines

Big Pharma Split (FRA:XN4) Cash-to-Debt : No Debt (1) (As of Jun. 2024)